A5025000498- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Viral gastroenteritis research and epidemiology
- Virus-based gene therapy research
- Animal Virus Infections Studies
- Advancements in Transdermal Drug Delivery
- Immunotherapy and Immune Responses
- Enzyme Production and Characterization
- Lipid Membrane Structure and Behavior
- Genomics and Phylogenetic Studies
- vaccines and immunoinformatics approaches
- Cancer therapeutics and mechanisms
- Pesticide and Herbicide Environmental Studies
- Viral Infections and Outbreaks Research
- biodegradable polymer synthesis and properties
- Microbial Natural Products and Biosynthesis
- Long-Term Effects of COVID-19
University of Pittsburgh
2021-2025
Pittsburg State University
2022-2023
Hazara University
2020
Czech Academy of Sciences, Institute of Microbiology
1987
Optimal vaccines are needed for sustained suppression of SARS-CoV-2 and other novel coronaviruses. Here, we developed a recombinant type 5 adenovirus vector encoding the gene S1 subunit antigen (Ad5.SARS-CoV-2-S1) COVID-19 immunization evaluated its immunogenicity in mice. A single with Ad5.SARS-CoV-2-S1 via S.C. injection or I.N delivery induced robust antibody cellular immune responses. Vaccination elicited significant S1-specific IgG, IgG1, IgG2a endpoint titers as early 2 weeks,...
This paper presents a novel approach for improving the efficacy of COVID-19 vaccines against emergent SARS-CoV-2 variants. We have evaluated immunogenicity unadjuvanted wild-type (WU S1-RS09cg) and variant-specific (Delta S1-RS09cg OM S1 subunit protein delivered either as monovalent or trivalent antigen in BALB/c mice. Our results show that induced broader humoral response with more coverage antigenically distinct variants, especially when compared to Omicron-specific S1. was also found...
Background/Objectives: COVID-19 vaccines effectively prevent severe disease, but unequal distribution, especially in low- and middle-income countries, has led to vaccine-resistant strains. This highlights the urgent need for alternative vaccine platforms that are safe, thermostable, easy distribute. study evaluates immunogenicity, stability, scalability of a dissolved microneedle array patch (MAP) delivering rS1RS09 subunit vaccine, comprising SARS-CoV-2 S1 monomer RS09, TLR-4 agonist...
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has raised concerns about reduced vaccine effectiveness and the increased risk infection, while repeated homologous booster shots are recommended for elderly immunocompromised individuals, they cannot completely protect against breakthrough infections. In our previous study, we assessed immunogenicity an adenovirus-based expressing SARS-CoV-2 S1 (Ad5.S1) in mice, which induced robust humoral cellular...
Additional COVID-19 vaccines that are safe and immunogenic needed for global vaccine equity. Here, we developed a recombinant type 5 adenovirus vector encoding the SARS-CoV-2 S1 subunit antigen nucleocapsid as fusion protein (Ad5.SARS-CoV-2-S1N). A single subcutaneous immunization with Ad5.SARS-CoV-2-S1N induced similar humoral response, along significantly higher S1-specific cellular alone (Ad5.SARS-CoV-2-S1). Immunogenicity was improved by homologous prime-boost vaccination, further...
A polyhydroxybutyrate (PHB)-degrading actinomycete, strain SFB5AT, was identified as a species of Streptomyces based on its membrane fatty acid profile and the presence ll-diaminopimelic in cell wall. It formed sporulating mycelia most agar media, but flat or wrinkled, moist colonies trypticase soy agar. Spores were smooth, cylindrical, borne long, straight to flexuous chains. produced light brown diffusible pigment, not melanin. Comparison genomic digital DNA-DNA hybridization (dDDH)...
ABSTRACT The coronavirus disease 2019 (COVID-19) pandemic has highlighted the need for safe and effective vaccines to be rapidly developed distributed worldwide, especially considering emergence of new severe acute respiratory syndrome 2 (SARS-CoV-2) variants. Protein subunit have emerged as a promising approach due their proven safety record ability elicit robust immune responses. In this study, we evaluated immunogenicity efficacy an adjuvanted tetravalent S1 protein COVID-19 vaccine...
Abstract Currently approved COVID-19 vaccines prevent symptomatic infection, hospitalization, and death of the disease. However, emergence severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants raises concerns reduced vaccine effectiveness increased risk infection. Repeated homologous booster in elderly individuals immunocompromised patients is considered to solve form disease caused by new SARS-CoV-2 but cannot protect completely against breakthrough In our previous study we...
The COVID-19 pandemic has highlighted the need for safe and effective vaccines to be rapidly developed distributed worldwide, especially considering emergence of new SARS-CoV-2 variants. Protein subunit have emerged as a promising approach due their proven safety record ability elicit robust immune responses. In this study, we evaluated immunogenicity efficacy an adjuvanted tetravalent S1 protein vaccine candidate composed Wuhan, B.1.1.7 variant, B.1.351 P.1 variant spike proteins in...
Tauseef Ahmad1,2, Haroon3#*, Muhammad Khan4#, Fazal Mehmood Khan5#, Taha Hussein Musa1,2#, Alfonso J Rodriguez-Morales6,7 and Jin Hui1,2 Author Affiliations 1Department of Epidemiology Health Statistics, School Public Health, Southeast University, Nanjing 210009, China 2Key Laboratory Environmental Medicine Engineering, Ministry Education, Nanjing, 3College Life Science, Northwest Xian, 4Department Genetics, Centre for Human Hazara University Mansehra, Khyber Pakhtunkhwa, Islamic Republic...
Abstract Additional COVID-19 vaccines that are safe, easy to manufacture, and immunogenic needed for global vaccine equity. Here, we developed a recombinant type 5 adenovirus vector encoding the SARS-CoV-2-S1 subunit antigen nucleocapsid as fusion protein (Ad5.SARS-CoV-2-S1N) delivered BALB/c mice through multiple administration routes. A single subcutaneous (S.C.) immunization with Ad5.SARS-CoV-2-S1N induced similar humoral response, along significantly higher S1-specific cellular S1 alone...
Abstract This paper presents a novel approach for improving the efficacy of COVID-19 vaccines against emergent SARS-CoV-2 variants. We have evaluated immunogenicity unadjuvanted wild-type (WU S1-RS09cg) and variant-specific (Delta S1-RS09cg OM S1 subunit protein delivered either as monovalent or trivalent antigen in BALB/c mice. Our results show that induced broader humoral response with more coverage antigenically distinct variants, especially when compared to Omicron-specific S1. was also...